Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check2 days agoChange DetectedAdded a note that the study is not recruiting participants. The revision tag was updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.3%

- Check9 days agoChange DetectedThe revision label at the bottom of the page updated from v3.5.4 to v3.5.5, signaling a new platform revision was deployed. This change does not modify study data, text, or core functionality visible to users.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision entry v3.5.4 was added to the record history, and the previous revision entry v3.5.3 was removed, indicating an update to the study record's versioning in the history view.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page’s interface revision label was updated from **v3.5.0** to **v3.5.3**, indicating a minor software/version change rather than a change to the clinical trial record itself.SummaryDifference0.1%

- Check88 days agoChange DetectedFooter revision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check102 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 in the page history.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.